Maximilian Merz, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, shared a post on LinkedIn:
“What a great way to start 2026
I am very greatful to have received a 2 Million Euro grant (2.3 Mill USD) by the Hector-stiftung to study the effects of CART cells and bispecific antibodies on the immune system of patients suffering from myeloma.
Not just since the incredible results from MajesTEC3 of Teclistamab after 1-3 lines of therapy, we are wondering what might be the best treatment sequence: CAR-T followed by bispecifics vice versa or combining both?
Together with my partner in crime Kristin Reiche from the Fraunhofer IZI, we will be able to find answers thanks to this generous support!”
More posts featuring Maximilian Merz.